This Whitepaper discusses the different approaches to real-time qPCR, outlines considerations to help quickly compare previously optimized qPCR assays with a new qPCR Master Mix, offers guidance for optimizing your real-time qPCR assay and provides a tool for comparing qPCR reagent formulations.
Roche bolstered the Swiss pharma giant’s diagnostics capabilities by acquiring the company’s long-term partner, TIB Molbiol. The procurement will expand Roche’s PCR-test portfolio capabilities in the ongoing fight against existing and emerging infectious diseases, including new Covid-19 variants of interest.
Shared in Mesoblast dropped on the last day of August 2021 after the Melbourne-based biotech was told that the company’s investigational respiratory treatment for Covid-19 needed to undergo another trial in order to receive emergency use authorization (EUA) from U.S. Food and Drug Administration.
British life sciences company NetScientific Plc said on June 7 that one of the company’s subsidiaries entered an exclusive licensing agreement with AstraZeneca Plc to globally sell a Covid-19 test.
Mission Bio launched the company’s Pharma Assay Development (PAD) service, enabling its customers to obtain early access services based on the newest technologies as well as on existing products.
Agilent Technologies, expanding on the company’s precision oncology testing, is acquiring Resolution Bioscience.
Caris Life Sciences secured $310 million in growth capital that will be used to expand the molecular science company’s presence in precision medicine in oncology.
This webinar will discuss a set of in vitro assays that tackle the challenges of in vitro hepatotoxicity assessment.
The U.S. Food and Drug Administration granted Ortho Clinical Diagnostics’ total antibody assay for COVID-19 Emergency Use Authorization.
Personal Genome Diagnostics Inc. reported that the cancer genomics company’s 500+ gene pan-cancer tumor profiling tissue assay is being used in Merck’s Phase 2 precision oncology KeyImPaCT study of biomarker-directed, pembrolizumab-based combination therapy for advanced non-small-cell lung cancer (KEYNOTE-495).